Anti-CDK6 Antibody, clone 2J3 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2J3 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects CDK6. It targets an epitope within 21 amino acids from the C-terminal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal region of human CDK6.
• Application: Anti-CDK6, clone 2J3 ZooMAb, Cat. No. ZRB1490, is a recombinant Rabbit monoclonal antibody that specifically targets CDK6 and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blotting.
• Target description: Cyclin-dependent kinase 6 (UniProt: Q00534; also known as EC:2.7.11.22, Cell division protein kinase 6, Cdk6, Serine/threonine-protein kinase PLSTIRE) is encoded by the CDK6 (also known as CDKN6) gene (Gene ID: 1021) in human. CDK6 is a ubiquitously expressed serine/threonine-protein kinase that is involved in the control of the cell cycle and differentiation. Its kinase domain is localized to amino acids 13-300 and its kinase activity is observed only in the nucleus. It associates with D-type cyclins (D1, D2 and D3), and the resulting complexes enable the cell to pass from the G1 phase to the S phase. Its binding to cyclin promotes its activation by phosphorylation at threonine 177. CDK6 is considered as a versatile player in transcriptional regulation and differentiation, participating in the integration of signaling networks and controlling changes in gene expression and epigenetic status, which contribute to cell fate determination. Over-expression of CDK6 has been reported in some leukemias and malignancies, including sarcoma, glioma, breast tumors, lymphoma, and melanoma. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Tigan., AS et al. (2016). Oncogene 35(24); 3083-3091).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 0.3 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.